Echo(1) | $15,000,000 | (Aug 1, 2025)
KredosAi | Undisclosed Amount | (Aug 1, 2025)
Cline | $32,000,000 | (Aug 1, 2025)
Certified by Founder
Lodge
NeuroSense Therapeutics
start up
United States
- Cambridge, Massachusetts
- 09/12/2021
- Unknown
- $12,000,000
Advancing research, development and therapy for ALS and additional CNS indications.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases.
Currently in preparations towards a Phase IIb in ALS patients in USA and Israel.
- Industry Biotechnology Research
- Website http://www.neurosense-tx.com/
- LinkedIn https://www.linkedin.com/company/neurosense-therapeutics/about/
Related People
Alon Ben-NoonCo Founder
Israel -
Herzliyya, Tel Aviv
Life Sciences Executive ; Leading NeuroSense Therapeutics, a Biotech startup which accelerates research, development and therapy for ALS (Amyotrophic Lateral Sclerosis) and additional Neurodegenerative diseases.
LinkedIn
https://www.linkedin.com/in/alonbn/
Moonshine AI | Undisclosed Amount | (Aug 1, 2025)
Noma Security | $100,000,000 | (Aug 1, 2025)
Anaconda, Inc. | $150,000,000 | (Aug 1, 2025)
Nebulock | $8,500,000 | (Aug 1, 2025)
MyPrize | $21,000,000 | (Aug 1, 2025)
Safe Security | $70,000,000 | (Aug 1, 2025)
Merso | $3,000,000 | (Aug 1, 2025)
Metaforms | $9,000,000 | (Aug 1, 2025)
Ultromics | $55,000,000 | (Jul 31, 2025)